Base de dados : MEDLINE
Pesquisa : D03.605.687.900 [Categoria DeCS]
Referências encontradas : 317 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 32 ir para página                         

  1 / 317 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28799582
[Au] Autor:Hodgkinson L
[Ad] Endereço:Clarivate Analytics, London, UK. lisa.hodgkinson@clarivate.com.
[Ti] Título:American Urological Association (AUA) - 112th Annual Meeting (May 12-16, 2017 - Boston, Massachusetts, USA).
[So] Source:Drugs Today (Barc);53(6):367-369, 2017 Jun.
[Is] ISSN:1699-3993
[Cp] País de publicação:Spain
[La] Idioma:eng
[Ab] Resumo:The American Urological Association (AUA) stands at the forefront of technology development and urological education for urologists and urological healthcare professionals worldwide. The 112th annual meeting brought together a wide range of researchers in the field of urology to access knowledge, up-to-date clinical guidelines and advances in research. The meeting consisted of plenary and moderated poster, podium and video sessions highlighting the latest research and advances in urological medicine. This report highlights some of the presentations on therapeutic developments for a range of urological conditions.
[Mh] Termos MeSH primário: Urologia/organização & administração
[Mh] Termos MeSH secundário: Acetanilidas/administração & dosagem
Administração Intranasal
Idoso
Idoso de 80 Anos ou mais
Antibióticos Antineoplásicos/administração & dosagem
Antibióticos Antineoplásicos/uso terapêutico
Carcinoma de Células de Transição/tratamento farmacológico
Ensaios Clínicos Fase III como Assunto
Desamino Arginina Vasopressina/administração & dosagem
Desamino Arginina Vasopressina/uso terapêutico
Preparações de Ação Retardada
Método Duplo-Cego
Combinação de Medicamentos
Seres Humanos
Hidrogéis
Mitomicina/administração & dosagem
Mitomicina/uso terapêutico
Estudos Multicêntricos como Assunto
Noctúria/tratamento farmacológico
Ensaios Clínicos Controlados Aleatórios como Assunto
Succinato de Solifenacina/administração & dosagem
Tiazóis/administração & dosagem
Estados Unidos
Neoplasias da Bexiga Urinária/tratamento farmacológico
Bexiga Urinária Hiperativa/tratamento farmacológico
[Pt] Tipo de publicação:CONGRESSES
[Nm] Nome de substância:
0 (Acetanilides); 0 (Antibiotics, Antineoplastic); 0 (Delayed-Action Preparations); 0 (Drug Combinations); 0 (Hydrogels); 0 (Thiazoles); 50SG953SK6 (Mitomycin); ENR1LLB0FP (Deamino Arginine Vasopressin); KKA5DLD701 (Solifenacin Succinate); MVR3JL3B2V (mirabegron)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170812
[St] Status:MEDLINE
[do] DOI:10.1358/dot.2017.53.6.2662981


  2 / 317 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28394529
[Au] Autor:Krivoborodov GG; Tur EI
[Ad] Endereço:Department of Urology and Andrology, Medical Faculty of N.I. Pirogov RNRMU of Minzdrav of Russia, Moscow.
[Ti] Título:[Comprehensive pharmacologic management of overactive bladder].
[So] Source:Urologiia;(1):82-88, 2017 Apr.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Overactive bladder (OAB) is a common and bothersome condition manifested by urgency, frequent urination, significantly impairing patients quality of life. The article presents an overview of the evidence on pharmacotherapy of neurogenic and idiopathic OAB. Selective M3 receptor blockers have been shown to be the medications of choice in treating these patients. Many studies have shown that solifenacin 10 mg is a starting dose for patients with OAB. Mirabegron (Betmiga) is the only 3-adrenergic receptor agonist approved for primary treatment of OAB patients refractory to anticholinergics or have their side effects. It seems promising to use this drug, both as monotherapy and concurrently with anticholinergic agents to improve treatment results in patients with idiopathic and neurogenic OAB.
[Mh] Termos MeSH primário: Bexiga Urinária Hiperativa/tratamento farmacológico
[Mh] Termos MeSH secundário: Acetanilidas/uso terapêutico
Agonistas de Receptores Adrenérgicos beta 3/uso terapêutico
Combinação de Medicamentos
Seres Humanos
Antagonistas Muscarínicos/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Succinato de Solifenacina/uso terapêutico
Sulfonamidas/uso terapêutico
Tiazóis/uso terapêutico
Bexiga Urinaria Neurogênica/tratamento farmacológico
Bexiga Urinaria Neurogênica/etiologia
Bexiga Urinária Hiperativa/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Acetanilides); 0 (Adrenergic beta-3 Receptor Agonists); 0 (Drug Combinations); 0 (Muscarinic Antagonists); 0 (Sulfonamides); 0 (Thiazoles); G3P28OML5I (tamsulosin); KKA5DLD701 (Solifenacin Succinate); MVR3JL3B2V (mirabegron)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170411
[St] Status:MEDLINE


  3 / 317 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28260277
[Au] Autor:Nalliah S; Wg P; Masten Singh PK; Naidu P; Lim V; Ahamed AA
[Ad] Endereço:PMP, KMN,DPMP, MBBS(Mal), FRCOG(Lond), FAMM(Mal), MEd, is a consultant obstetrician and gynecologist and Head, Division of Human Development and Population Health, Clinical School, International Medical University, Jalan Rasah, Seremban, Malaysia.
[Ti] Título:Comparison of efficacy and tolerability of pharmacological treatment for the overactive bladder in women: A network meta-analysis.
[So] Source:Aust Fam Physician;46(3):139-144, 2017 Mar.
[Is] ISSN:0300-8495
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Overactive bladder syndrome (OAB) is a common medical condition that causes significant distress and impact on the quality of life in women. Muscarinic receptor antagonists remain the mainstay of therapy, but they are limited by their efficacy and adverse effects. The objective of the article was to compare the clinical efficacy and tolerability of medications used to treat OAB in women through network meta-analysis. METHODS: Data from eligible studies of commonly prescribed pharmacological agents in the treatment of OAB in women were entered into Net-MetaXL after a literature search using two online databases (PubMed and Cochrane). Studies between 31 July 2000 and 31 July 2015 were included in this study. RESULTS: Five quantitative studies were eligible for analysis. The most efficacious drug to treat OAB in women appears to be solifenacin 10 mg once daily (OD), followed by oxybutynin 3 mg three times a day. However, solifenacin 10 mg OD caused more adverse effects that the other treatments. DISCUSSION: Our results are similar to those of another systematic review. When considering efficacy, tolerability and cost, solifenacin 5 mg once daily is the drug of choice as it is more efficacious, albeit with more adverse effects, than other treatments. If solifenacin is unsuitable, oxybutynin 3 mg TDS is recommended.
[Mh] Termos MeSH primário: Ácidos Mandélicos/uso terapêutico
Succinato de Solifenacina/uso terapêutico
Bexiga Urinária Hiperativa/tratamento farmacológico
Agentes Urológicos/uso terapêutico
[Mh] Termos MeSH secundário: Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Ácidos Mandélicos/efeitos adversos
Ensaios Clínicos Controlados Aleatórios como Assunto
Succinato de Solifenacina/efeitos adversos
Agentes Urológicos/efeitos adversos
Saúde da Mulher
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Mandelic Acids); 0 (Urological Agents); K9P6MC7092 (oxybutynin); KKA5DLD701 (Solifenacin Succinate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170707
[Lr] Data última revisão:
170707
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170306
[St] Status:MEDLINE


  4 / 317 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28166296
[Au] Autor:Drake MJ; Oelke M; Snijder R; Klaver M; Traudtner K; van Charldorp K; Bongaerts D; Van Kerrebroeck P
[Ad] Endereço:University of Bristol, Bristol, United Kingdom.
[Ti] Título:Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies.
[So] Source:PLoS One;12(2):e0170726, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The emergence of urinary retention (UR), specifically acute urinary retention (AUR), has been a concern when treating men with lower urinary tract symptoms (LUTS) with antimuscarinic drugs. MATERIALS AND METHODS: In NEPTUNE (12-week, double-blind), men (≥45 years) with LUTS were randomized to receive tamsulosin oral-controlled absorption system (TOCAS) 0.4 mg, fixed-dose combination (FDC) of solifenacin (Soli) 6 mg + TOCAS 0.4 mg, FDC Soli 9 mg + TOCAS 0.4 mg, or placebo. In NEPTUNE II (40-week, open-label extension of NEPTUNE), continuing patients received 4-week FDC Soli 6 mg + TOCAS, then FDC Soli 6 mg or 9 mg + TOCAS for the remainder of the study, switchable every 3 months. RESULTS: Across both studies, 1208 men received ≥1 dose of FDC Soli 6 mg or 9 mg + TOCAS for up to 52 weeks; 1199 men completed NEPTUNE and 1066 received ≥1 dose in NEPTUNE II. In total, 13 men (1.1%; 95% CI, 0.6%-1.8%) reported a UR event while receiving FDC, eight of which were AUR (0.7%; 95% CI, 0.3%-1.3%, incidence 7/1000 man-years). Six men reported UR events while taking Soli 6 mg + TOCAS (three AUR), and seven men reported a UR event while taking Soli 9 mg + TOCAS (five AUR). One man developed AUR while taking TOCAS alone and four reported UR (three AUR) during placebo run-in. Most AUR/UR events occurred within 4 months of treatment initiation. CONCLUSIONS: FDC Soli and TOCAS was associated with a low rate of UR and AUR in men with LUTS.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/complicações
Succinato de Solifenacina/efeitos adversos
Sulfonamidas/efeitos adversos
Retenção Urinária/epidemiologia
Retenção Urinária/etiologia
Agentes Urológicos/efeitos adversos
[Mh] Termos MeSH secundário: Combinação de Medicamentos
Seres Humanos
Incidência
Sintomas do Trato Urinário Inferior/tratamento farmacológico
Masculino
Fatores de Risco
Succinato de Solifenacina/administração & dosagem
Sulfonamidas/administração & dosagem
Comprimidos
Fatores de Tempo
Retenção Urinária/diagnóstico
Agentes Urológicos/administração & dosagem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Sulfonamides); 0 (Tablets); 0 (Urological Agents); G3P28OML5I (tamsulosin); KKA5DLD701 (Solifenacin Succinate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170825
[Lr] Data última revisão:
170825
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170207
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0170726


  5 / 317 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28147376
[Au] Autor:Hampel C; Betz D; Burger M; Nowak C; Vogel M
[Ad] Endereço:Department of Urology, University Medical Center of the Johannes-Gutenberg University, Mainz, Germany.
[Ti] Título:Solifenacin in the Elderly: Results of an Observational Study Measuring Efficacy, Tolerability and Cognitive Effects.
[So] Source:Urol Int;98(3):350-357, 2017.
[Is] ISSN:1423-0399
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The study aimed to evaluate the efficacy and safety of solifenacin in older patients with overactive bladder (OAB). MATERIALS AND METHODS: Observational data on patients aged ≥70 years and the prescribed flexible dose of solifenacin for OAB were collected at 294 offices of German general practitioners. Baseline and week 12 data included type and severity of OAB symptoms, adverse events, quality of life, and change in cognitive function per Mini Mental State Examination (MMSE). RESULTS: Mean age of 774 patients was 78 ± 6 years. A decrease was observed in all OAB symptoms including a reduction of urinary urgency and micturition, each by 4 episodes per 24 h. No change in mean MMSE scores was apparent at week 12. Adverse events and treatment discontinuations were low at 5.8 and 0.5%, respectively. CONCLUSION: Solifenacin was well-tolerated while OAB symptoms declined at week 12. No relevant effect of solifenacin on cognitive function was observed in this elderly population.
[Mh] Termos MeSH primário: Transtornos Cognitivos/induzido quimicamente
Succinato de Solifenacina/efeitos adversos
Succinato de Solifenacina/uso terapêutico
Bexiga Urinária Hiperativa/complicações
Bexiga Urinária Hiperativa/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Cognição/efeitos dos fármacos
Transtornos Cognitivos/psicologia
Feminino
Alemanha
Seres Humanos
Masculino
Meia-Idade
Antagonistas Muscarínicos/efeitos adversos
Antagonistas Muscarínicos/uso terapêutico
Qualidade de Vida
Resultado do Tratamento
Bexiga Urinária Hiperativa/psicologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Muscarinic Antagonists); KKA5DLD701 (Solifenacin Succinate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170202
[St] Status:MEDLINE
[do] DOI:10.1159/000455257


  6 / 317 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28074677
[Au] Autor:Kosilov K; Loparev S; Kuzina I; Shakirova O; Zhuravskaya N; Lobodenko A
[Ad] Endereço:a Department of Social Sciences , Far Eastern Federal University , Vladivostok , Russia.
[Ti] Título:The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms.
[So] Source:Aging Male;20(1):39-44, 2017 Mar.
[Is] ISSN:1473-0790
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Study of validity of the Medication Adherence Self-Report Inventory (MASRI) for use in clinical practice to treat patients with benign prostatic obstruction (BPO) accompanied with overactive bladder (OAB) symptoms. METHODS: During 12 weeks of the randomized study, 452 patients with BPO and OAB symptoms (mean age of 61.3 (12.7)) were studied for adherence to the treatment with Tamsulosin, Solifenacin and Trospium using the MASRI. External monitoring instruments included the Brief Medication Questionnaire (BMQ) and the visual remaining pill count. The state of the prostate gland and the lower urinary tract was monitored using questionnaires I-PSS, OAB Awareness Tool, uroflowmetry and voiding diaries. RESULT: Correlation between the percentage of men non-adherent to treatment (MASRI) and the percentage of patients having a belief barrier on the screen of the BMQ was r = 0.89, p ≤0.05, r = 0.92, p ≤0.01, r = 0.85, p ≤0.05, a number of missed doses on the Regimen Screen of the BMQ was r = 0.79; p ≤0.05; r = 0.81; p ≤0.05; r = 0.75, p ≤0.05, a number of non-adherent patients according to the BMQ was r = 0.83 (p ≤0.05), r = 0.88 (p ≤0.05), r = 0.79, p ≤0.05, the results of the pill count were r = 0.65-0.76; p ≤0.05-0.01. These data confirm high validity of the MASRI. CONCLUSION: The MASRI is a valid tool for rapid assessment of adherence to treatment of patients with BPO and OAB receiving Tamsulosin and antimuscarinic drugs and may be recommended for use in clinical practice.
[Mh] Termos MeSH primário: Adesão à Medicação
Hiperplasia Prostática/tratamento farmacológico
Autoavaliação
Bexiga Urinária Hiperativa/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Benzilatos/uso terapêutico
Autoavaliação Diagnóstica
Quimioterapia Combinada
Seres Humanos
Masculino
Meia-Idade
Antagonistas Muscarínicos/uso terapêutico
Nortropanos/uso terapêutico
Hiperplasia Prostática/complicações
Succinato de Solifenacina/uso terapêutico
Sulfonamidas/uso terapêutico
Inquéritos e Questionários
Bexiga Urinária Hiperativa/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Benzilates); 0 (Muscarinic Antagonists); 0 (Nortropanes); 0 (Sulfonamides); 1E6682427E (trospium chloride); G3P28OML5I (tamsulosin); KKA5DLD701 (Solifenacin Succinate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170112
[St] Status:MEDLINE
[do] DOI:10.1080/13685538.2016.1247435


  7 / 317 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28049246
[Au] Autor:Lee SD; Chung JM; Kang DI; Ryu DS; Cho WY; Park S
[Ad] Endereço:Department of Urology, Pusan National University Yangsan Hospital and Research Institute for Convergence of Biomedical Science and Technology, Yangsan, Korea.
[Ti] Título:Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study.
[So] Source:J Korean Med Sci;32(2):329-334, 2017 Feb.
[Is] ISSN:1598-6357
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:We investigated the efficacy and tolerability of solifenacin 5 mg fixed dose in children with newly diagnosed idiopathic overactive bladder (OAB). A total of 34 children (male/female patients = 16/18) aged under 13 years (mean age: 7.2 ± 2.3; range: 5-12) who were newly diagnosed with OAB from January 2012 to September 2014 were prospectively evaluated with open-label protocol. All patients were treated with solifenacin 5 mg fixed dose once daily for at least 4 weeks. The efficacy and tolerability of solifenacin were evaluated 4, 8, and 12 weeks after the initiation of treatment. The mean voiding frequency during daytime was decreased from 9.4 ± 3.0 to 6.5 ± 2.3 times after the 12-week treatment (P < 0.001). The mean total OAB symptom score (OABSS) decreased from 7.7 ± 4.2 to 3.1 ± 3.1 after the 12-week treatment (P < 0.001). The urgency and urgency urinary incontinence (UUI) domains significantly improved from the 12-week treatment, and complete resolution of urgency occurred in 38.9% of patients and the percentage of children with UUI among urgent patients decreased from 79.4% to 57.1%. According to 3-day voiding diaries, the average bladder capacity increased from 90.4 ± 44.4 to 156.2 ± 67.3 mL (P < 0.001). Drug-induced adverse effects (AEs) were reported in 7 patients (20.6%). Our results indicate that solifenacin 5 mg fixed dose is effective against OAB symptoms, and its tolerability is acceptable without significant AEs in children with OAB.
[Mh] Termos MeSH primário: Succinato de Solifenacina/uso terapêutico
Bexiga Urinária Hiperativa/tratamento farmacológico
Agentes Urológicos/uso terapêutico
[Mh] Termos MeSH secundário: Grupo com Ancestrais do Continente Asiático
Criança
Pré-Escolar
Tolerância a Medicamentos
Fadiga/etiologia
Feminino
Seres Humanos
Masculino
Estudos Prospectivos
República da Coreia
Succinato de Solifenacina/efeitos adversos
Resultado do Tratamento
Incontinência Urinária/patologia
Micção
Agentes Urológicos/efeitos adversos
Xerostomia/etiologia
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Urological Agents); KKA5DLD701 (Solifenacin Succinate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170331
[Lr] Data última revisão:
170331
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170104
[St] Status:MEDLINE
[do] DOI:10.3346/jkms.2017.32.2.329


  8 / 317 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27809592
[Au] Autor:Dellis AE; Papatsoris AG; Keeley FX; Bamias A; Deliveliotis C; Skolarikos AA
[Ad] Endereço:1 Second Department of Surgery, School of Medicine, Aretaieion Hospital, National and Kapodistrian University of Athens , Maroussi, Greece .
[Ti] Título:Tamsulosin, Solifenacin, and Their Combination for the Treatment of Stent-Related Symptoms: A Randomized Controlled Study.
[So] Source:J Endourol;31(1):100-109, 2017 Jan.
[Is] ISSN:1557-900X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To properly use the Ureteric Symptom Score Questionnaire (USSQ) to evaluate, in a randomized control study, the effect of tamsulosin, solifenacin, and their combination in improving symptoms and quality of life in patients with indwelling ureteral stents. MATERIALS AND METHODS: After institutional review board approval, 260 patients with a ureteral stent were randomly assigned to receive tamsulosin 0.4 mg, solifenacin 5 mg, or placebo and further randomized to receive their combination. The validated USSQ was completed 1 and 4 weeks after stent insertion and 4 weeks after stent removal. Kruskal-Wallis test, chi-squared test (or Fisher's exact test), one-way analysis of variance, and T-test (or Wilcoxon rank-sum test if not normal data) were used for statistical analysis. The results were considered significant at p < 0.05. RESULTS: Patients receiving tamsulosin or solifenacin expressed significantly lower urinary (p < 0.001), pain (p < 0.001 with stent in situ), and general health index (p = 0.002 in first and p < 0.001 in fourth week with stent in situ) scores. Sexual life and quality of work were also positively influenced. Patients on combination therapy expressed lower urinary (p < 0.001) and pain (p < 0.001) scores in the fourth week with stent in situ and work performance in the first week and with stent in situ (p = 0.001) and after stent removal (p = 0.005). No patients had to discontinue medication due to side effects. CONCLUSIONS: Stent-related morbidity is a reality in the majority of patients. Simple medication, such as tamsulosin and solifenacin alone or in combination, improves stent-related symptoms and has a positive impact on quality of life.
[Mh] Termos MeSH primário: Succinato de Solifenacina/administração & dosagem
Stents/efeitos adversos
Sulfonamidas/administração & dosagem
Agentes Urológicos/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Dor/tratamento farmacológico
Medição da Dor
Estudos Prospectivos
Qualidade de Vida
Inquéritos e Questionários
Ureter/cirurgia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Sulfonamides); 0 (Urological Agents); G3P28OML5I (tamsulosin); KKA5DLD701 (Solifenacin Succinate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161105
[St] Status:MEDLINE
[do] DOI:10.1089/end.2016.0663


  9 / 317 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27605255
[Au] Autor:Cardozo L; Herschorn S; Snijder R; Siddiqui E; Chapple CR
[Ad] Endereço:Department of Urogynaecology, King's College Hospital, Denmark Hill, London, SE5 9RS, UK. linda@lindacardozo.co.uk.
[Ti] Título:Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?
[So] Source:Int Urogynecol J;28(3):477-488, 2017 Mar.
[Is] ISSN:1433-3023
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION AND HYPOTHESIS: Pooled data from seven randomized placebo-controlled trials were analysed to evaluate relationships between baseline body mass index (BMI), gender or age and the efficacy/tolerability of solifenacin (5 - 10 mg daily) in patients with overactive bladder (OAB). METHODS: Changes in efficacy variables from baseline to 12 weeks were compared in patients with symptoms at baseline between solifenacin-treated and placebo-treated groups. Normalization rates were calculated (no more than eight micturitions in 24 h, no more than one episode of nocturia per night, zero values for other variables over 24 h). Treatment-emergent adverse events (TEAEs) were recorded. RESULTS: The baseline incidence of incontinence and urgency incontinence increased with increasing BMI and age; relatively more women than men were incontinent. The baseline incidence of urgency was similar between genders and among age groups, but tended to increase with increasing BMI. The baseline frequencies of micturition and nocturia were similar in all BMI categories, between genders and in all age groups. The results from this meta-analysis of an integrated database of data from trials investigating solifenacin showed that solifenacin was more efficacious than placebo for all OAB symptoms across all BMI and age categories, and between genders. Normalization rates for micturition frequency, incontinence and urgency were greater in patients receiving solifenacin than in those receiving placebo across all categories. The overall incidence of TEAEs was higher in patients receiving solifenacin than in those receiving placebo; solifenacin was generally well tolerated in both groups. The overall frequency of TEAEs for solifenacin and placebo was slightly higher in women than in men and in older than in younger patients. The most commonly reported TEAEs were dry mouth and constipation. CONCLUSIONS: Regardless of BMI, gender or age, all patients with OAB can be considered candidates for solifenacin treatment.
[Mh] Termos MeSH primário: Fatores Etários
Índice de Massa Corporal
Antagonistas Muscarínicos/administração & dosagem
Fatores Sexuais
Succinato de Solifenacina/administração & dosagem
Bexiga Urinária Hiperativa/tratamento farmacológico
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
Ensaios Clínicos Controlados Aleatórios como Assunto
Incontinência Urinária/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Muscarinic Antagonists); KKA5DLD701 (Solifenacin Succinate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160909
[St] Status:MEDLINE
[do] DOI:10.1007/s00192-016-3130-5


  10 / 317 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27514371
[Au] Autor:Abrams P; Kelleher C; Staskin D; Kay R; Martan A; Mincik I; Newgreen D; Ridder A; Paireddy A; van Maanen R
[Ad] Endereço:Bristol Urological Institute, Southmead Hospital, BS10 5NB, Bristol, UK. paul.abrams@bui.ac.uk.
[Ti] Título:Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).
[So] Source:World J Urol;35(5):827-838, 2017 May.
[Is] ISSN:1433-8726
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: This large dose-ranging study explored the benefits of different combinations of mirabegron and solifenacin on health-related quality of life (HRQoL), based on patient-reported outcomes (PROs), and patients ('responders') achieving clinically meaningful improvements in efficacy and HRQoL. METHODS: SYMPHONY (NCT01340027) was a Phase II, placebo- and monotherapy-controlled, dose-ranging, 12-week trial. Adult patients with overactive bladder (OAB) for ≥3 months were randomized to 1 of 12 groups: 6 combination (solifenacin 2.5/5/10 mg + mirabegron 25/50 mg), 5 monotherapy (solifenacin 2.5/5/10 mg, or mirabegron 25/50 mg), or placebo. Change from baseline to end of treatment was assessed, versus placebo and solifenacin 5 mg in: PROs (OAB-q [Symptom Bother/total HRQoL] and Patient Perception of Bladder Condition score), and responders achieving minimally important differences (MIDs) in PROs and predetermined clinically meaningful improvements in efficacy (e.g. <8 micturitions/24 h). Changes in PROs and responders were analysed using an ANCOVA model and logistic regression, respectively. RESULTS: The Full Analysis Set included 1278 patients. Combination therapy of solifenacin 5/10 mg + mirabegron 25/50 mg significantly improved PROs versus solifenacin 5 mg and placebo, and significantly more responders achieved MIDs in PROs and efficacy. Micturition frequency normalization was approximately twofold greater with 10 + 25 mg (OR 2.06 [95 % CI 1.11, 3.84; p = 0.023]) and 5 + 50 mg (OR 1.91 [95 % CI 1.14, 3.21; p = 0.015]) versus solifenacin 5 mg. CONCLUSION: Combining mirabegron 25/50 mg and solifenacin 5/10 mg improves objective and subjective efficacy outcomes compared with placebo or solifenacin 5 mg.
[Mh] Termos MeSH primário: Acetanilidas/administração & dosagem
Qualidade de Vida
Succinato de Solifenacina/administração & dosagem
Tiazóis/administração & dosagem
Bexiga Urinária Hiperativa/tratamento farmacológico
Agentes Urológicos/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Método Duplo-Cego
Quimioterapia Combinada
Feminino
Nível de Saúde
Seres Humanos
Masculino
Meia-Idade
Diferença Mínima Clinicamente Importante
Medidas de Resultados Relatados pelo Paciente
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Acetanilides); 0 (Thiazoles); 0 (Urological Agents); KKA5DLD701 (Solifenacin Succinate); MVR3JL3B2V (mirabegron)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160813
[St] Status:MEDLINE
[do] DOI:10.1007/s00345-016-1908-1



página 1 de 32 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde